ZSZhi-Xin Shan

Zhi-Xin Shan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhi-Xin Shan has a total of 257 co-authors. Here are the top co-authors by number of shared publications:

  • Qiu-Xiong Lin

    Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangzhou 510080, China

    18 shared publications
  • Jie-Ning Zhu

    Key Laboratory of Clinical Pharmacology Guangdong Provincial Health Commission, Medical Research Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China

    15 shared publications
  • Yong-Heng Fu

    Research Center of Medical Sciences, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China

    14 shared publications
  • Xi-Yong Yu

    13 shared publications
  • Chun-Yu Deng

    Research Center of Medical Sciences, Guangdong Provincial People's Hospital, Guangzhou 510080, PR China

    12 shared publications
  • Hui Li

    Key Laboratory of Clinical Pharmacology Guangdong Provincial Health Commission, Medical Research Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China

    7 shared publications

Latest Publications

  • The cardiac protective human circular RNA circKLHL20_009 sponges miR-31-5p to ameliorate myocardial hypertrophy and fibrosis through suppressing β-catenin signaling

    by Yi-Hong Wen, Jia-Xue Jiang, Wen-Yan Dong, Jing Guo, Qing-Yue Hu, Xiao-Yao Liu, Zhen-Zhen Yang, Lu-Fang Huang, Jie-Ning Zhu, Meng-Zhen Zhang, et al.

  • Open Access

    Circular RNAs as potential therapeutics and novel biomarkers for heart failure

    by Ruohan Li, Xuemin Su, Jiaxue Jiang, Jinfeng Su, Jiening Zhu, Jindong Xu, Zhixin Shan

    Heart failure (HF) is a type of chronic pathological remodeling in which the heart fails to efficiently supply an adequate amount of blood to fulfill the body’s requirements. Circular RNAs (circRNAs) are recognized as specific types of long noncoding RNAs that are involved in the regulation of the pathogenesis of cardiovascular diseases, including cardiac remodeling and HF. In this review, knowledge about the origin, characteristics, and function of circRNAs is summarized. The regulatory function of circRNAs in cardiac remodeling mechanisms, including cell death, cardiac hypertrophy, fibrosis and mitochondrial metabolism, is reviewed. Finally, future directions for investigating the diagnostic and pharmacological potential of circRNAs in HF are proposed.


  • S1UTRSP5, a short restructured RNA from SLIT1 3′UTR, mitigates mouse cardiac remodeling via enhancing SlRT1 activity

    by Jin-Feng Su, Tao Ou, Xiao-Yao Liu, Xue-Min Su, Ya Wang, Yi-Hong Wen, Yuan Gao, Ruo-Han Li, Lu-Fang Huang, Chuan-Meng Zhou, et al.

    The 3′ untranslated regions (3′UTRs) have been known to regulate mRNA location, stability, and translation. 3′UTR length regulation is involved in the pathogenesis of cardiac dysfunction; however, more about the roles of 3′UTRs in cardiac remodeling remains elusive. In this study, we found slit guidance ligand 1 (SLIT1) 3′UTR with 3074 nt in length, which was 10-fold higher than SLIT1 coding sequence (CDS), was significantly decreased in the myocardium of patients with heart failure (HF) (n = 40) in comparison with healthy organ donors (n=17). We revealed that SLIT1 3′UTR and the 1526 nt fragment of SLIT1 3′UTR (FS1UTR) mainly and specifically combined miR-34a-5p, and improved cardiac remodeling through the miR-34a-5p/SIRT1 axis independently of Slit1 expression. Furthermore, a 260 nt restructured RNA derived from FS1UTR, S1UTRSP5, which contains 5 binding sites of miR-34a-5p seed sequence, alleviated cardiac remodeling in vitro and in vivo. We demonstrated that S1UTRSP5 blocked the function of miR-34a-5p and activated the SIRT1-PGC-1α-Nrf2 axis in cardiomyocytes, and promoted the SIRT1/Smad3 signal in cardiac fibroblasts and the SIRT1-eNOS-VEGFA axis in endothelial cells, collectively contributing to the amelioration of cardiac remodeling. These results provide new insights into the development of S1UTRSP5 as a novel inhibitor of miR-34a-5p for cardiac remodeling and HF. The alternative text for this image may have been generated using AI. The human SLIT1 3′UTR or FS1UTR combines miR-34a-5p to increase SIRT1 level in CMs, CFs and ECs. Notably, S1UTRSP5, a 260-nt stable RNA derived from SLIT1 3′UTR, efficiently sponged miR-34a-5p to activate SIRT1-PGC-1α-Nrf2 pathway in CMs, and to promote SIRT1/Smad3 signal in CFs and the SIRT1-eNOS-VEGFA pathway in ECs, collectively contributing to amelioration of cardiac remodeling.

  • circSP199a, a circularized RNA sponge targeting miR-199a-5p and -3p, mitigates mouse cardiac hypertrophy and fibrosis

    by Hua-Yan Wu, Chuan-Meng Zhou, Yuan Gao, Yi-Hong Wen, Ya-Ting Hu, Heng-Li Zhao, Wen-Yan Dong, Xiao-Yao Liu, Lin Zhai, Yi Li, et al.

    Increasing evidence shows that microRNAs (miRNAs) are functionally associated with cardiac remodeling. Functionally, some cytoplasmic circRNAs may act as miRNA sponges to inhibit functions of the combined miRNAs. Our previous study showed that miR-199a-5p and -3p promote cardiac hypertrophy and fibrosis. In this study, we designed and synthesized a novel circularized RNA sponge, circSP199a, and evaluated the therapeutic effects of circSP199a against cardiac hypertrophy and fibrosis. The synthesized circSP199a included 6 repeats of reverse complements of seed sequences of miR-199a-5p and -3p with 515 nt in length. We showed that the synthesized circSP199a and expression vector-mediated circSP199a expression inhibited cardiomyocyte hypertrophy and mitigated the fibrotic phenotypes in neonatal mouse cardiac fibroblasts and human cardiac organoid fibrosis via the combination of miR-199a-5p and -3p. Furthermore, intravenous injection of AAV9-circSP199a for 21 days in advance significantly ameliorated transverse aortic constriction-induced cardiac injury and remodeling in mice. We demonstrated that circSP199a blocked the functions of miR-199a-5p and -3p to enhance the expression of target genes of PGC-1α, Rb1, Sirt1 and Smad1 both in vitro and in vivo. These results provide new insights into the development of RNA sponge-based therapies for cardiac hypertrophy and fibrosis. The artificial circSP199a functions as a novel inhibitor of miR-199a-5p and -3p, exogenous provision of circSP199a specifically sponges miR-199a-5p and -3p to block their functions with subsequent upregulations of the target genes, including PGC-1α, Rb1, SIRT1 and Smad1, to mitigate the pathological cardiac hypertrophy and fibrosis.


  • Open Access

    CircSARS-CV2-N1368 from SARS-CoV-2 impairs endothelial cell function through the upregulation of ATF7 to activate TLR4/NF-κB/ROS signaling

    by Yi-Hong Wen, Heng-Li Zhao, Shao-Yu Wu, Jia-Xue Jiang, Yuan Gao, Zi-Fan Wang, Xiao-Yao Liu, Fei Yu, Tao Ou, An-Zhi Zhao, et al.

    SARS-CoV-2 can encode circular RNAs (circRNAs); however, the potential effects of exogenous SARS-CoV-2 circRNAs on cardiovascular sequelae remain unknown. Three circRNAs derived from the nucleocapsid (N) gene of SARS-CoV-2, namely, circSARS-CV2-Ns, were identified for functional studies. In particular, circSARS-CV2-N1368 was shown to enhance platelet adhesiveness to endothelial cells (ECs) and inhibit EC-dependent vascular relaxation. Moreover, exogenous expression of circSARS-CV2-N1368 suppressed EC proliferation and migration and decreased angiogenesis and cardiac organoid beating. Mechanistically, we elucidated that circSARS-CV2-N1368 sponged the microRNA miR-103a-3p, which could reverse circSARS-CV2-N1368-induced EC damage. Additionally, activating transcription factor 7 (ATF7) was identified as a target gene of miR-103a-3p, and Toll-like receptor 4 (TLR4) was verified as a downstream gene of ATF7 that mediates circARS-CV2-N1368-induced activation of nuclear factor kappa B (NF-κB) signaling and ROS production in ECs. Importantly, the reactive oxygen species (ROS) scavenger NAC mitigated the circSARS-CV2-N1368-promoted EC impairment. Our findings reveal that the TLR4/NF-κB/ROS signal pathway is critical for mediating circSARS-CV2-N1368-promoted oxidative damage in ECs, providing insights into the endothelial impairment caused by circSARS-CV2-Ns.


  • Open Access

    New Types of Post-Translational Modification of Proteins in Cardiovascular Diseases

    by Juntao Fang, Shaoyu Wu, Hengli Zhao, Chuanmeng Zhou, Ling Xue, Zhiyong Lei, Hui Li, Zhixin Shan

    Post-translational modifications (PTMs), which are covalent alterations of proteins after their synthesis, are critical for their proper function and the maintenance of cellular physiology. The significance of PTMs in the context of cardiovascular diseases (CVDs) has been increasingly recognized due to their potential to influence protein stability, activity, and localization, thereby affecting the progression of CVDs. The identification and understanding of PTMs in CVDs at the molecular level are vital for the discovery of new biomarkers and new targets for clinical interventions. This article provides a comprehensive overview of the role and mechanisms of new types of PTMs, such as acetylation, crotonylation, succinylation, S-nitrosylation, malonylation, S-palmitonylation, β-hydroxybutyrylation and lactylation, in CVDs, highlighting their importance in advancing diagnostic and therapeutic approaches for CVDs. Graphical Abstract


  • Open Access

    Prognostic Value of Depressive Symptoms for Cardiovascular Events in Female Patients With Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction

    by Hengli Zhao, Jiaxue Jiang, Guoheng Zhong, You Peng, Yihong Wen, Yu Liang, Zhixin Shan

    Background: Among those with heart failure (HF), women are more likely to develop depression than men. Few studies have focused on the outcomes of female patients with HF with depressive symptoms. Methods and Results: A total of 506 female patients with HF with preserved ejection fraction were included in this secondary analysis from the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) cohort, and 439 female patients with HF with reduced ejection fraction were included from the HF‐ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) cohort. Depressive symptoms were measured using the Patient Health Questionnaire‐9 and Beck Depression Inventory‐II. The depression class was categorized by severity, and the change in clinical depression class was defined as aggravated (1‐grade increase) or improved (1‐grade decrease). The prognostic value of depressive symptoms was determined by using multivariable Cox proportional hazards models. Female patients with improved depressive symptoms had worse depressive status at baseline and lower baseline Kansas City Cardiomyopathy Questionnaire scores. Depression class at the 12‐month visit and depression class change were the dominant prognostic factors for cardiovascular death in female patients with HF with preserved ejection fraction (hazard ratio [HR], 1.43 [95% CI, 1.02–2.01], P =0.036; HR, 1.71 [95% CI, 1.14–2.55], P =0.009). Among the patients with HF with reduced ejection fraction, both the depression class at baseline and depression class change had significant prognostic effects on cardiovascular death (HR, 3.30 [95% CI, 1.70–6.39], P P =0.004). However, the prognostic value of depressive assessments for hospitalization in patients with HF is unclear. Conclusions: In female patients with HF with reduced ejection fraction, the depression class at baseline was most strongly associated with cardiovascular death, whereas in female patients with HF with preserved ejection fraction, the change in depression class exhibited a more significant prognostic trend.


  • Suppression of the Inhibitory Effect of circ_0036176-Translated Myo9a-208 on Cardiac Fibroblast Proliferation by miR-218-5p

    by Jing Guo, Li-Wen Chen, Zhi-Qi Huang, Ji-Shen Guo, Hui Li, Yue Shan, Ze-Run Chen, Yu-Min Yan, Jie-Ning Zhu, Hui-Ming Guo, et al.

    Increasing evidence has shown that circular RNAs (circRNAs) participate in the process of cardiac remodeling. CircRNA circ_0036176 originating from the back-splicing of exon 2 to exon4 of myosin IXA (Myo9a) gene was shown to be increased in the myocardium of patients with heart failure (HF) and riched in exosomes from human AC16 cardiomyocytes with overexpression of circ_0036176. Proliferation activity was inhibited in mCFs subjected to exosomal circ_0036176 treatment and in mCFs with overexpression of circ_0036176. Interestingly, circ_0036176 contains an IRES element and an ORF of 627 nt encoding a 208-amino acid protein (termed as Myo9a-208). Myo9a-208 was shown to mediate the inhibitory effect of circ_0036176 on CFs proliferation, and miR-218-5p could inhibit Myo9a-208 expression by binding to circ_0036176, resulting in abolishing the effect of circ_0036176 on inactivating cyclin/Rb signal and suppressing CFs proliferation. Our findings suggest that circ_0036176 inhibits mCFs proliferation by translating Myo9a-208 protein to suppress cyclin/Rb pathway. Graphical abstract


  • Open Access

    Diverging targets mediate the pathological role of miR-199a-5p and miR-199a-3p by promoting cardiac hypertrophy and fibrosis

    by Ni Zeng, Yu-Qing Huang, Yu-Min Yan, Zhi-Qin Hu, Zhuo Zhang, Jia-Xin Feng, Ji-Shen Guo, Jie-Ning Zhu, Yong-Heng Fu, Xi-Pei Wang, et al.


  • Dickkopf 3: a Novel Target Gene of miR-25-3p in Promoting Fibrosis-Related Gene Expression in Myocardial Fibrosis

    by Ni Zeng, Yi-Hong Wen, Rong Pan, Jing Yang, Yu-Min Yan, An-Zhi Zhao, Jie-Ning Zhu, Xian-Hong Fang, Zhi-Xin Shan

    Increasing evidence has shown that microRNAs (miRNAs) participate in cardiac fibrosis. We aimed to elucidate the effect of miRNA miR-25-3p on cardiac fibrosis. MiRNA microarray was used to profile miRNAs in the myocardium of angiotensin-II (Ang-II)-infused mice. Effect of miR-25-3p on expression of fibrosis-related genes, including Col1a1, Col3a1, and Acta2, was investigated both in vitro and in vivo. MiR-25-3p was shown increased in the myocardium of Ang-II-infused mice and patients with heart failure. MiR-25-3p enhanced fibrosis-related gene expression in mouse cardiac fibroblasts (mCFs) and in the myocardium of Ang-II-infused mice. Dickkopf 3 (Dkk3) was identified as a target gene of miR-25-3p, and Dkk3 could ameliorate Smad3 activation and fibrosis-related gene expression via enhancing Smad7 expression in mCFs. Additionally, NF-κB signal was proven to mediate upregulation of miR-25-3p in cardiac fibrosis. Our findings suggest that miR-25-3p enhances cardiac fibrosis by suppressing Dkk3 to activate Smad3 and fibrosis-related gene expression. Graphical abstract